Last updated: May 29, 2026

Application No. 18/407,053

SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS

Final Rejection

Filed

Jan 08, 2024

Priority

Apr 06, 2018 — provisional 62/654,108 +5 more

Examiner

O DELL, DAVID K

Art Unit

1621

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Biocryst Pharmaceuticals Inc.

OA Round

2 (Final)

This examiner grants 58% of cases after interview

— +35.8% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 1338 resolved cases, 2023–2026

Examiner Intelligence

O DELL, DAVID K View full profile →

Grants 58% of resolved cases

Career Allowance Rate

773 granted / 1338 resolved

-2.2% vs TC avg

Strong +36% interview lift

Without

With

+35.8%

Interview Lift

resolved cases with interview

Typical timeline

2y 9m

Avg Prosecution

39 currently pending

Career history

1386

Total Applications

across all art units

Statute-Specific Performance

§101

1.2%

-38.8% vs TC avg

§103

41.8%

+1.8% vs TC avg

§102

6.4%

-33.6% vs TC avg

§112

18.9%

-21.1% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1338 resolved cases

Prosecution Timeline

Jan 08, 2024

Application Filed

Apr 21, 2025

Non-Final Rejection mailed

Jul 21, 2025

Response Filed

Sep 08, 2025

Final Rejection mailed

Apr 04, 2026

Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

17/426,187

Patent 12637411

STRUCTURALLY MODIFIED OPIOIDS FOR PREVENTION AND TREATMENT OF DISEASES AND CONDITIONS

4y 10m to grant Granted May 26, 2026

17/622,096

Patent 12636368

IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY

4y 5m to grant Granted May 26, 2026

17/609,856

Patent 12630526

PROCESSES FOR PREPARING AMINOPYRIMIDINE COMPOUNDS

4y 6m to grant Granted May 19, 2026

17/630,714

Patent 12630514

PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PYROXASULFONE

4y 3m to grant Granted May 19, 2026

17/755,907

Patent 12630509

HETEROCYCLIC NMDA ANTAGONISTS

4y 0m to grant Granted May 19, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

58%

Grant Probability

94%

With Interview (+35.8%)

2y 9m (~4m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 1338 resolved cases by this examiner. Grant probability derived from career allowance rate.